Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|AKT1 E17K||Advanced Solid Tumor||sensitive||Capivasertib||Phase II||Actionable||In a Phase II (MATCH) trial, Capivasertib (AZD5363) treatment resulted in partial response in 23% (8/35) and stable disease in 46% (16/35) of patients with advanced solid tumors harboring AKT1 E17K mutation (PMID: 30429128; NCT02465060).||30429128|
|AKT1 E17K||Advanced Solid Tumor||sensitive||Capivasertib||Phase I||Actionable||In a Phase I trial, Capivasertib (AZD5363) demonstrated safety and preliminary antitumor activity in patients with advanced solid tumors, resulted in stable disease in 27% (10/37) of patients and partial response in two patients, both of whom harbored an AKT1 E17K mutation (PMID: 26931343; NCT01353781).||26931343 detail...|
|PubMed Id||Reference Title||Details|
|459P A Phase I study to assess the safety and tolerability of the selective Akt inhibitor AZD5363 in Japanese patients with advanced solid tumours||Full reference...|
|(26931343)||Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.||Full reference...|
|(30429128)||Capivasertib Active against AKT1-Mutated Cancers.||Full reference...|